| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H24F3N3O2 |
| Molecular Weight | 431.4508 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C(=O)N1C3=CC=C(OCCCN4CCCC4)C=C3)C(=CC=C2)C(F)(F)F
InChI
InChIKey=DDDZBLNULGDPGA-UHFFFAOYSA-N
InChI=1S/C23H24F3N3O2/c1-16-27-20-7-4-6-19(23(24,25)26)21(20)22(30)29(16)17-8-10-18(11-9-17)31-15-5-14-28-12-2-3-13-28/h4,6-11H,2-3,5,12-15H2,1H3
| Molecular Formula | C23H24F3N3O2 |
| Molecular Weight | 431.4508 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MK-0249 is a potent H3 receptor inverse agonist patented by Abbott Laboratories for treatment of cognitive deficits. MK-0249 demonstrates promising results in preclinical models of cognitive disorders. MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia ets. Unfortunately, MK-0249 failed to demonstrate efficacy in schizophrenia, mild-to-moderate Alzheimer's Disease, attention-deficit/hyperactivity disorder, and future development has been discontinued.
